Boston, MA 10/16/2013 (wallstreetpr) – Opko Health Inc. (NYSE:OPK), a multinational pharmaceutical and diagnostic company incorporated in 1991 October, has announced its decision to invest in Zebra Biologics Inc, a biotech company that is privately held. This is under what the company has termed “strategic investment.”
Zebra Biologics is in the business of discovery and development of bio-super antibody therapeutics as well other complex drugs.
By investing in Zebra Biologics, OPK is seeking a portfolio into its investment that has room and potential for appreciation. OPK also has interest in companies which show valuable proprietary technologies which can reward as they mature. This is why Philip Frost, OPK chairman and CEO said that, “this participation is in keeping with our core strategy.”
By pursuing investment in such promising companies as Zebra Biologics, OPK has the potential of obtaining news technologies, expanding its market horizons and monetizing its new products for better revenue collection.
There are several indications tha OPK is poised for some good performance this season and in the near future. Perhaps this is best illustrated by the CEO’s recent purchase valued at $84,405 of OPK shares. This transaction occurred when the shares of the pharmaceutical and diagnostic company were valued at $9.93 per share, thus buying 8,500 shares.
Investors seeking to follow insider maneuvers can follow suit and add this stock to their investment portfolio.
OPK has recently been a study subject of several equities researchers. Analysts at Jefferies Group have placed a “buy” rating on the stock with a price objective $10, having reviewed the same from $9 in the previous rating report. Another rating agency Barrington Research has maintained its “buy” rating on the stock in its most recent report.
The company currently has one year range of $4.20 low and $12.84 high. It has $4.96 billion in market value as of Wednesday, October 16.
